New technologies in proteomics and their applications in discovery-based research of tumor markers

Transcript

1 Chinese Bulletin of Life Sciences Vol. 17, No. 2 Apr., (2005) Q503; Q816; R730.4 A New technologies in proteomics and their applications in discovery-based research of tumor markers XU Qing-Wen,ZHANG Yu-Xia,WANG Yue-Dan,YIN Yan-Hui,CHEN Wei-Feng* (Department of Immunology, Peking University Health Science Center, Beijing , China) Abstract: With the development in genomic research, protemics has become an extremely active and increasingly important part of the worldwide life science research and the core of the functional genomics era or the postgenomic era. Several new technologies in proteomics developed in the past few years greatly boosted the discovery-based research of tumor markers beyond the disadvantages of traditional approaches. Nevertheless, rules of evidence to access the validity of results, important in any research, are crucial in discovery-based research. Follow these rules, some current problems might be predictable and avoidable so that results could be of accuracy, precision and effectiveness. Key words: proteomics; tumor marker; laser capture microdissection; TOF-MS; imaging MS [1] [2~3] (one-at-a-time approach) (G ) (1981 ) (1981 ) (1972 ) (1968 ) (1935 ) *

2 142 [4] 1 2D-PAGE (two-dimensional polyacrylamide gel electrophoresis, 2D-PAGE) [5] [6] [7] [8] [9] [10] 2D-PAGE 2D-PAGE (laser capture microdissection, LCM ) 2D-PAGE LCM [11] LCM DNA RNA LCM LCM DNA RNA [11] LCM (NIH) Arcturus (USA) PALM Mikrolaser Technolgie(Germany) Leica(Germany) LCM [8] Ornstein [12] LCM 3

3 LCM LCM Jones [13] LCM 2D-PAGE 5 2 (low malignant potential LMP) 3 (invasive ovarian cancer) LCM 2D-PAGE (ion trap MS) (HPLC) 52 kd FK506 RhoGDI glyoxalase I 2.2 (time-of-flight mass spectrometry, TOF-MS) (matrix-assisted laser desorption ionization time-of-flight mass spectrometry, MALDI-TOF MS) (surface-enhanced laser desorption ionization time-of-flight mass spectrometry, SELDI-TOF MS) (energy absorb molecular, EAM) ( m/z) m/z Petricoin [14] SELDI-TOF MS (PSA) 70%( ) PSA>4ng/ml 95% 21 PSA Adam [15] (train) 9 96% 91% PSA Petricoin [16] 100% 95% Paweletz [17] LCM SELDI- TOF LCM SELDI-TOF Paweletz [18] Sauter [19] (nipple aspirate fluid NAF)

4 144 TOF-MS (LC) (ESI) ( LC-ESI- MALDI-TOF) (peptide mass fingerprinting PMF) [20] MALDI-TOF MS Gygi [21~22] (isotope-coded affinity tag ICAT) [23] TOF-MS TOF-MS (fmol) 500D~500kD TOF-MS TOF-MS TOF-MS 2.3 (imaging mass spectrometry,imaging MS) [24] MALDI-TOF MS (m/z) MALDI-TOF MS ( 1) 1 [24] 12 µm [ (acetonitrile) (SPA sinapinic acid) ] 30 1 MALDI-TOF MS MALDI-TOF MS 50µm 15~50 Stoeckli [24] 82 3 m/z m/z m/z (D54)

5 145 1cm D D D HPLC (electrospray MS) MALDI-MS Tβ.4 [25] Caprioli [26] (CEA) 100% [27] CEA CEA [28] (bias) Ransohoff [29] 4 [30~32] [23,33] ; [1] Kahn P. From genome to proteome: looking at a cell s proteins. Science, 1995, 270: 369~370 [2] Pandey A, Mann M. Proteomics to study genes and genomes. Nature, 2000, 405(6788): 837~846 [3] Tyers M, Mann M. From genomics to proteomics. Nature, 2003, 422(6928): 193~197 [4] Ransohoff D F. Developing molecular biomarkers for cancer. Science, 2003, 299(5613): 1679~1680 [5] Franzen B, Linder S, Alaiya A A, et al. Analysis of polypeptide expression in benign and malignant human breast lesions. Electrophoresis, 1997, 18: 582~587 [6] Soldes O S, Kuick R D, Thompson I A, et al. Differential expression of Hsp27 in normal oesophagus, Barrett s metaplasia and oesophageal adenocarcinomas. Br J Cancer, 1999, 79: 595~603 [7] Celis J E, Celis P, Ostergaard M, et al. Proteomics and

6 146 immunohistochemistry define some of the steps involved in the squamous differentiation of the bladder transitional epithelium: a novel strategy for identifying metaplastic lesions.cancer Res, 1999, 59(12): 3003~3009 [8] Seow T K, Liang R C, Leow C K, et al. Hepatocellular carcinoma: from bedside to proteomics. Proteomics, 2001, 1 (10): 1249~1263 [9] Chen G, Gharib T G, Huang C C, et al. Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin Cancer Res, 2002, 8(7): 2298~2305 [10] Meehan K L, Holland J W, Dawkins H J, et al. Proteomic analysis of normal and malignant prostate tissue to identify novel proteins lost in cancer. Prostate, 2002, 50(1): 54~63 [11] Emmert-Buck M R, Bonner R F, Smith P D, et al. Laser capture microdissection. Science, 1996, 274(5289): 998~1001 [12] Ornstein D K, Gillespie J W, Paweletz C P, et al. Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis, 2000, 21: 2235~2242 [13] Jones M B, Krutzsch H, Shu H J, et al. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics, 2002, 2: 76~84 [14] Petricoin E F, Ornstein D K, Paweletz C P, et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst, 2002, 94(20): 1576~1578 [15] Adam B L, Qu Y, Davis J W, et al.serum protein finger printing coupled with a pattern matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res, 2002, 62: 3609~3614 [16] Petricoin E F, Ardekani A M, Hitt B A, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet, 2002, 359: 572~577 [17] Paweletz C P, Gillespie J W, Ornstein D K, et al. Rapid protein display profiling of cancer progression directly from human tissue using a protein biochip. Drug Dev Res, 2000, 49: 34~42 [18] Paweletz C P, Trock B, Pennanen M, et al. Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer. Dis Markers, 2001, 17(4): 301~307 [19] Sauter E R, Zhu W, Fan X J, et al. Proteomic analysis of nipple aspirate fluid to detect biologic markers of breast cancer. Br J Cancer, 2002, 86(9): 1440~1443 [20] Mann M, Hojrup P, Roepstorff P. Use of mass spectrometric molecular weight information to identify proteins in sequence databases. Biol Mass Spectrom, 1993, 22(6): 338~345 [21] Gygi S P, Rist B, Gerber S A, et al. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol, 1999, 17: 994~999 [22] Gygi S P, Rist B, Aebersold R, et al. Measuring gene expression by quantitative protein analysis. Curr Opin Biotechnol, 2000, 11: 396~401 [23] Li C, Hong Y, Tan Y X, et al. Accurate qualitative and quantitative proteomic analysis of clinical hepatocellular carcinoma using laser capture microdissection coupled with isotope-coded affinity tag and two-dimensional liquid chromatography mass spectrometry. Mol Cell Proteomics, 2004, 3(4): 399~409 [24] Stoeckli M, Chaurand P, Hallahan D E, et al. Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nat Med, 2001, 7: 493~496 [25] Hall A K. Differential expression of thymosin genes in human tumors and in the developing human kidney. Int J Cancer, 1991, 48(5): 672~677 [26] Caprioli R M, Farmer T B, Gile J, et al. Molecular imaging of biological samples: localization of peptides and proteins using MALDI-TOF MS. Anal Chem, 1997, 69(23): 4751~4760 [27] Thomson D M, Krupey J, Freedman S O, et al.the radioimmunoassay of circulating carcinoembryonic antigen of the human digestive system. Proc Natl Acad Sci USA, 1969, 64: 161~167 [28] Ransohoff D F, Feinstein A R. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N Engl J Med, 1978, 299: 926~930 [29] Ransohoff D F. Rules of evidence for cancer molecularmarker discovery and validation. Nat Rev Cancer, 2004, 4(4): 309~314 [30] Wasinger V C, Cordwell S J, Cerpa-Poljak A, et al. Progress with gene product mapping of the Mollicutes: Mycoplasma genitalium. Electrophoresis, 1995, 16: 1090~1094 [31] Persidis A. Proteomics. Nat Biotechnol, 1998, 16(4): 393~394 [32] Gerisow M J. Proteomics: one small step for a digital computer, one giant leap for humankind. Nat Biotechnol, 1998, 16(2): 206 [33] Cyranoski D. China takes centre stage for liver proteome. Nature, 2003, 425(6957): 441